Citation： 四川大学华西医院肝癌MDT团队. 肝细胞肝癌全程多学科规范化管理：华西医院多学科专家共识（第二版）. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(9): 1062-1077. doi: 10.7507/1007-9424.202006102 Copy
| 1. | Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108. |
| 2. | Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132. |
| 3. | 中华人民共和国卫计委. 原发性肝癌诊疗规范 (2017 年版). 中华消化外科杂志, 2017, 16(7): 635-647. |
| 4. | 中华人民共和国卫健委. 原发性肝癌诊疗规范(2019 年版). 中国实用外科杂志, 2020, 40(2): 121-138. |
| 5. | 四川大学华西医院肝癌 MDT 团队. 肝细胞癌切除术后复发转移的防治: 华西医院多学科专家共识. 中国普外基础与临床杂志, 2017, 24(8): 927-939. |
| 6. | Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371. |
| 7. | Ryder SD, British Society of gastroenterology. guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut, 2003, 52 Suppl 3(Suppl 3): i1-i8. |
| 8. | Force USPST. Grade definitions and suggestions for practice. 2012. https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions. |
| 9. | European Association For The Study Of The Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol, 2012, 56(4): 908-943. |
| 10. | Omata M, Cheng AL, Kokudo N, et al. Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int, 2017, 11(4): 317-370. |
| 11. | Park MJ, Kim YK, Lee MW, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology, 2012, 264(3): 761-770. |
| 12. | Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced mr imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology, 2010, 256(3): 806-816. |
| 13. | Mitchell DG, Bruix J, Sherman M, et al. LI-RADS (liver imaging reporting and data system): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology, 2015, 61(3): 1056-1065. |
| 14. | Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol, 2016, 54(12): 1296-1305. |
| 15. | Johnson PJ. The BALAD-2 and GALAD biomarker models for hepatocellular carcinoma. Gastroenterol Hepatol (N Y), 2017, 13(4): 231-233. |
| 16. | Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol, 2016, 22(42): 9279-9287. |
| 17. | Huang C, Zhu XD, Ji Y, et al. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona clinic liver cancer (BCLC) stages 0 or B. BMC Cancer, 2017, 17(1): 58. |
| 18. | 中华医学会外科学分会肝脏外科学组. 肝细胞癌外科治疗方法的选择专家共识(2016 年第 3 次修订). 中华消化外科杂志, 2017, 16(2): 113-115. |
| 19. | Shen JY, Li C, Wen TF, et al. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the milan criteria after hepatectomy. J Surg Res, 2017, 209: 102-111. |
| 20. | Chen YK, Hsieh DS, Liao CS, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res, 2005, 25(6C): 4719-4725. |
| 21. | 文天夫. 转化切除是提高肝细胞癌切除率的重要途径. 中国普外基础与临床杂志, 2020, 27(2): 133-136. |
| 22. | Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery, 1990, 107(5): 521-527. |
| 23. | Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255(3): 405-414. |
| 24. | 周俭, 王征, 孙健, 等. 联合肝脏离断和门静脉结扎的二步肝切除术. 中华消化外科杂志, 2013, 12(7): 485-489. |
| 25. | 彭驰涵, 李川, 文天夫, 等. 原发性肝癌行 ALPPS 的适应证与禁忌证初探 (附 15 例报道). 中国普外基础与临床杂志, 2015, 22(10): 1183-1186. |
| 26. | Guiu B, Chevallier P, Denys A, et al. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol, 2016, 26(12): 4259-4267. |
| 27. | 刘畅, 张晓赟, 金谌, 等. 肝静脉系统栓堵术在第二阶段根治性肝癌切除术中的应用. 中国普外基础与临床杂志, 2019, 26(7): 841-846. |
| 28. | Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg, 1998, 15(6): 674-678. |
| 29. | Irtan S, Chopin-Laly X, Ronot M, et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int, 2011, 31(5): 740-743. |
| 30. | 余业勤, 汤钊猷, 周信达, 等. 大肝癌的分阶段治疗. 中华外科杂志, 1983, 21(2): 92-93. |
| 31. | Ronot M, Cauchy F, Gregoli B, et al. Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. HPB (Oxford), 2016, 18(8): 684-690. |
| 32. | Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res, 2018, 24(9): 2074-2081. |
| 33. | Kanai T, Hirohashi S, Upton MP, et al. Pathology of small hepatocellular carcinoma. Cancer, 1987, 60(4): 810-819. |
| 34. | Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg, 2009, 249(1): 118-123. |
| 35. | Hui AM, Takayama T, Sano K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol, 2000, 33(6): 975-979. |
| 36. | Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl, 2005, 11(9): 1086-1092. |
| 37. | Shirabe K, Toshima T, Kimura K, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int, 2014, 34(6): 937-941. |
| 38. | Lee S, Kim SH, Lee JE, et al. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol, 2017, 67(3): 526-534. |
| 39. | Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg, 2016, 151(4): 356-363. |
| 40. | Li C, Shen JY, Zhang XY, et al. Predictors of futile liver resection for patients with barcelona clinic liver cancer stage B/C hepatocellular carcinoma. J Gastrointest Surg, 2018, 22(3): 496-502. |
| 41. | Li C, Liu JY, Peng W, et al. Liver resection versus transplantation for multiple hepatocellular carcinoma: a propensity score analysis. Oncotarget, 2017, 8(46): 81492-81500. |
| 42. | 中国医师协会肝癌专业委员会. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识 (2018 年版). 中国实用外科杂志, 2019, 39(1): 46-52. |
| 43. | Li J, Yan LN, Yang J, et al. Indicators of prognosis after liver transplantation in chinese hepatocellular carcinoma patients. World J Gastroenterol, 2009, 15(33): 4170-4176. |
| 44. | Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 2010, 59(7): 953-962. |
| 45. | Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology, 2013, 57(4): 1458-1468. |
| 46. | Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol, 2018, 33(2): 347-354. |
| 47. | Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol, 2015, 63(1): 83-92. |
| 48. | Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol, 2019, 37(24): 2141-2151. |
| 49. | Liu CL, Fan ST, Cheung ST, et al. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg, 2006, 244(2): 194-203. |
| 50. | Zheng JL, Shen S, Jiang L, et al. Outcomes of anterior approach major hepatectomy with diaphragmatic resection for single huge right lobe HCC with diaphragmatic invasion. Medicine (Baltimore), 2018, 97(36): e12194. |
| 51. | Man K, Fan ST, Ng IO, et al. Prospective evaluation of pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg, 1997, 226(6): 704-711. |
| 52. | Wen T, Chen Z, Yan L, et al. Continuous normothermic hemihepatic vascular inflow occlusion over 60 min for hepatectomy in patients with cirrhosis caused by hepatitis B virus. Hepatol Res, 2007, 37(5): 346-352. |
| 53. | Liu L, Wang ZW, Jiang SQ, et al. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One, 2013, 8(5): e64261. |
| 54. | Lee KF, Wong J, Cheung SYS, et al. Does intermittent pringle maneuver increase postoperative complications after hepatectomy for hepatocellular carcinoma? A randomized controlled trial. World J Surg, 2018, 42(10): 3302-3311. |
| 55. | Lu Q, Luo Y, Yuan CX, et al. Value of contrast-enhanced intraoperative ultrasound for cirrhotic patients with hepatocellular carcinoma: a report of 20 cases. World J Gastroenterol, 2008, 14(25): 4005-4010. |
| 56. | 方驰华, 张鹏, 罗火灵, 等. 增强现实导航技术联合吲哚菁绿分子荧光影像在三维腹腔镜肝切除术中的应用. 中华外科杂志, 2019, 57(8): 578-584. |
| 57. | Wu H, Lu Q, Luo Y, et al. Application of contrast-enhanced intraoperative ultrasonography in the decision-making about hepatocellular carcinoma operation. World J Gastroenterol, 2010, 16(4): 508-512. |
| 58. | Zhou C, Peng Y, Zhou K, et al. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. Hepatobiliary Surg Nutr, 2019, 8(1): 19-28. |
| 59. | Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol, 2016, 64(3): 594-600. |
| 60. | Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg, 2007, 245(1): 36-43. |
| 61. | Shen JY, Li C, Wen TF, et al. A simple prognostic score system predicts the prognosis of solitary large hepatocellular carcinoma following hepatectomy. Medicine (Baltimore), 2016, 95(31): e4296. |
| 62. | Eguchi S, Kanematsu T, Arii S, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery, 2008, 143(4): 469-475. |
| 63. | Han J, Li ZL, Xing H, et al. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford), 2019, 21(8): 962-971. |
| 64. | Makino Y, Yamanoi A, Kimoto T, et al. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol, 2000, 95(5): 1294-1300. |
| 65. | Buczkowski AK, Kim PT, Ho SG, et al. Multidisciplinary management of ruptured hepatocellular carcinoma. J Gastrointest Surg, 2006, 10(3): 379-386. |
| 66. | Kim BW, Kim YB, Wang HJ, et al. Risk Factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol, 2006, 12(1): 99-104. |
| 67. | Zhu WJ, Huang CY, Li C, et al. Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 2013, 14(12): 7101-7106. |
| 68. | Lee CW, Chan KM, Lee CF, et al. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg, 2011, 34(2): 53-62. |
| 69. | Nobuoka D, Kato Y, Gotohda N, et al. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep, 2010, 24(2): 521-528. |
| 70. | Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis b virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol, 2013, 31(29): 3647-3655. |
| 71. | 中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南. 北京: 人民卫生出版社, 2018: 35-38. |
| 72. | Ren ZG, Lin ZY, Xia JL, et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol, 2004, 10(19): 2791-2794. |
| 73. | Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg, 2009, 198(3): 313-318. |
| 74. | Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res, 2010, 40(10): 943-953. |
| 75. | Li KW, Wen TF, Li X, et al. The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion. Hepatogastroenterology, 2012, 59(118): 1944-1946. |
| 76. | Zhong JH, Li H, Li LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol, 2012, 38(4): 286-295. |
| 77. | Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond), 2018, 38(1): 61. |
| 78. | 程树群, 吴孟超, 陈汉, 等. 肝癌患者术后肝动脉化疗栓塞联合胸腺肽治疗预防复发的随机对照研究. 中华肿瘤杂志, 2004, 26(5): 305-307. |
| 79. | Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int, 2009, 3(3): 480-489. |
| 80. | He C, Peng W, Li C, et al. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. Medicine (Baltimore), 2017, 96(16): e6606. |
| 81. | Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 2000, 356(9232): 802-807. |
| 82. | Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology, 2000, 32(2): 228-232. |
| 83. | Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol, 2006, 132(7): 458-465. |
| 84. | Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg, 2007, 245(6): 831-842. |
| 85. | Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg, 2009, 96(9): 975-981. |
| 86. | Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res, 2014, 44(5): 523-531. |
| 87. | Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends, 2014, 8(6): 333-338. |
| 88. | Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2015, 16(13): 1344-1354. |
| 89. | Kudo M, Finn RS, Qin SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126): 1163-1173. |
| 90. | Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med, 2019, 8(1): 137-146. |
| 91. | Mizuta T, Ozaki I, Eguchi Y, et al. The Effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer, 2006, 106(4): 867-872. |
| 92. | Kakizaki S, Sohara N, Sato K, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol, 2007, 22(4): 518-522. |
| 93. | Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology, 2011, 54(2): 532-540. |
| 94. | Okita K, Izumi N, Matsui O, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol, 2015, 50(2): 191-202. |
| 95. | Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 2013, 31(28): 3501-3508. |
| 96. | Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol, 2010, 17(12): 3137-3144. |
| 97. | Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B E antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol, 2007, 47(5): 684-690. |
| 98. | Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg, 2015, 261(1): 56-66. |
| 99. | Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther, 2011, 33(10): 1104-1112. |
| 100. | Zhou XD, Tang ZY, Ma ZC, et al. Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. J Cancer Res Clin Oncol, 2009, 135(8): 1067-1072. |
| 101. | Si MS, Amersi F, Golish SR, et al. Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival. Am Surg, 2003, 69(10): 879-885. |
| 102. | Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol, 2005, 20(11): 1781-1787. |
| 103. | Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery, 2007, 141(2): 196-202. |
| 104. | Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer, 2000, 89(3): 500-507. |
| 105. | Lee KF, Chong CCN, Fong AKW, et al. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center. Hepatobiliary Surg Nutr, 2018, 7(5): 320-330. |
| 106. | Sakamoto M, Hirohashi S, Tsuda H, et al. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol, 1989, 13(12): 1064-1067. |
| 107. | Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg, 1989, 19(1): 98-129. |
| 108. | Takenaka K, Adachi E, Nishizaki T, et al. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology, 1994, 19(4): 889-894. |
| 109. | Ng IO, Guan XY, Poon RT, et al. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol, 2003, 199(3): 345-353. |
| 110. | Chen PJ, Chen DS, Lai MY, et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology, 1989, 96(2 Pt 1): 527-529. |
| 111. | Hodges KB, Cummings OW, Saxena R, et al. Clonal origin of multifocal hepatocellular carcinoma. Cancer, 2010, 116(17): 4078-4085. |
| 112. | Wang B, Xia CY, Lau WY, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg, 2013, 217(6): 1054-1062. |
| 113. | Morimoto O, Nagano H, Sakon M, et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol, 2003, 39(2): 215-221. |
| 114. | Esumi M, Aritaka T, Arii M, et al. Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res, 1986, 46(11): 5767-5771. |
| 115. | Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet, 2003, 361(9361): 923-929. |
| 116. | Cheung ST, Chen X, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res, 2002, 62(16): 4711-4721. |
| 117. | Barry CT, D'Souza M, McCall M, et al. Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant, 2012, 12(2): 428-437. |
| 118. | Wilkens L, Bredt M, Flemming P, et al. Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J Pathol, 2000, 192(1): 43-51. |
| 119. | Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 2012, 366(10): 883-892. |
| 120. | Miao R, Luo H, Zhou H, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol, 2014, 61(4): 840-849. |
| 121. | Xu XF, Xing H, Han J, et al. Risk Factors, Patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg, 2019, 154(3): 209-217. |
| 122. | Xing H, Zhang WG, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford), 2020, 22(5): 677-689. |
| 123. | Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg, 2017, 104(11): 1433-1442. |
| 124. | Meniconi RL, Komatsu S, Perdigao F, et al. Recurrent hepatocellular carcinoma: a western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery, 2015, 157(3): 454-462. |
| 125. | Zhang X, Li C, Wen T, et al. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J Gastroenterol Hepatol, 2015, 27(8): 933-940. |
| 126. | Wang DY, Liu L, Qi XS, et al. Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2015, 16(13): 5573-5578. |
| 127. | Mise Y, Hasegawa K, Shindoh J, et al. The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg, 2015, 262(2): 347-357. |
| 128. | Yamashita Y, Shirabe K, Tsuijita E, et al. Third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery, 2013, 154(5): 1038-1045. |
| 129. | Wu CC, Cheng SB, Yeh DC, et al. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg, 2009, 96(9): 1049-1057. |
| 130. | Poon RT, Fan ST, O'Suilleabhain CB, et al. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg, 2002, 195(3): 311-318. |
| 131. | Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg, 2003, 238(5): 703-710. |
| 132. | Zou Q, Li J, Wu D, et al. Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg Oncol, 2016, 23(8): 2618-2626. |
| 133. | Yamashita S, Aoki T, Inoue Y, et al. Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Surgery, 2015, 157(3): 463-472. |
| 134. | Nakajima Y, Ko S, Kanamura T, et al. Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg, 2001, 192(3): 339-344. |
| 135. | 董家鸿, 郑树森, 陈孝平, 等. 肝切除术前肝脏储备功能评估的专家共识(2011 版). 中华消化外科杂志, 2011, 10(1): 20-25. |
| 136. | Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology, 1997, 26(5): 1176-1181. |
| 137. | Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg, 1999, 188(3): 304-309. |
| 138. | Shindoh J, D Tzeng CW, Vauthey JN. Portal vein embolization for hepatocellular carcinoma. Liver Cancer, 2012, 1(3-4): 159-167. |
| 139. | Siriwardana RC, Lo CM, Chan SC, et al. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study. World J Surg, 2012, 36(7): 1640-1646. |
| 140. | Tsujita E, Utsunomiya T, Ohta M, et al. Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older. Surgery, 2010, 147(5): 696-703. |
| 141. | Liu K, Chen Y, Wu X, et al. Laparoscopic liver re-resection is feasible for patients with posthepatectomy hepatocellular carcinoma recurrence: a propensity score matching study. Surg Endosc, 2017, 31(11): 4790-4798. |
| 142. | Chan AC, Poon RT, Chok KS, et al. Feasibility of laparoscopic re-resection for patients with recurrent hepatocellular carcinoma. World J Surg, 2014, 38(5): 1141-1146. |
| 143. | Hu M, Zhao G, Xu D, et al. Laparoscopic repeat resection of recurrent hepatocellular carcinoma. World J Surg, 2011, 35(3): 648-655. |
| 144. | Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer, 2016, 35: 25. |
| 145. | Kanazawa A, Tsukamoto T, Shimizu S, et al. Laparoscopic liver resection for treating recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, 2013, 20(5): 512-517. |
| 146. | Belli G, Cioffi L, Fantini C, et al. Laparoscopic redo surgery for recurrent hepatocellular carcinoma in cirrhotic patients: feasibility, safety, and results. Surg Endosc, 2009, 23(8): 1807-1811. |
| 147. | Halls MC, Cipriani F, Berardi G, et al. Conversion for unfavorable intraoperative events results in significantly worse outcomes during laparoscopic liver resection: lessons learned from a multicenter review of 2861 cases. Ann Surg, 2018, 268(6): 1051-1057. |
| 148. | Fan J, Wu ZQ, Zhou J, et al. Hepatocellular carcinoma associated with tumor thrombosis in the portal vein: the effects of different treatments. Hepatobiliary Pancreat Dis Int, 2003, 2(4): 513-519. |
| 149. | Ye JZ, Wang YY, Bai T, et al. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the asia-pacific region beyond the barcelona clinic liver cancer treatment algorithms: a review and update. Oncotarget, 2017, 8(54): 93258-93278. |
| 150. | Tantawi B, Cherqui D, Tran van Nhieu J, et al. Surgery for biliary obstruction by tumour thrombus in primary liver cancer. Br J Surg, 1996, 83(11): 1522-1525. |
| 151. | Qin LX, Ma ZC, Wu ZQ, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients. World J Gastroenterol, 2004, 10(10): 1397-1401. |
| 152. | Satoh S, Ikai I, Honda G, et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery, 2000, 128(5): 779-783. |
| 153. | Liu QY, Lai DM, Liu C, et al. A Special recurrent pattern in small hepatocellular carcinoma after treatment: bile duct tumor thrombus formation. World J Gastroenterol, 2011, 17(43): 4817-4824. |
| 154. | Hanaoka J, Shimada M, Ikegami T, et al. Hepatocellular carcinoma with massive bile duct tumor thrombus: report of a long-term survival. Hepatogastroenterology, 2008, 55(88): 2217-2220. |
| 155. | Moon DB, Hwang S, Wang HJ, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study. World J Surg, 2013, 37(2): 443-451. |
| 156. | Wong TC, Cheung TT, Chok KS, et al. Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus. HPB (Oxford), 2015, 17(5): 401-408. |
| 157. | Xu LB, Liu C. Hepatocellular carcinoma with bile duct tumor thrombus: extrahepatic bile duct preserving or not? Ann Surg, 2017, 266(6): e62-e63. |
| 158. | Chen XP, Wu ZD, Huang ZY, et al. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg, 2005, 92(3): 334-339. |
| 159. | Zhang X, Li C, Wen T, et al. Synchronous splenectomy and hepatectomy for patients with small hepatocellular carcinoma and pathological spleen: neutrophil to lymphocyte ratio changes can predict the prognosis. Oncotarget, 2017, 8(28): 46298-46311. |
| 160. | Zhang XY, Li C, Wen TF, et al. Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: a case-control study. World J Gastroenterol, 2015, 21(8): 2358-2366. |
| 161. | Zhang Y, Wen TF, Yan LN, et al. Preoperative predictors of portal vein thrombosis after splenectomy with periesophagogastric devascularization. World J Gastroenterol, 2012, 18(15): 1834-1839. |
| 162. | 张晓赟, 李川, 彭伟, 等. 血小板/脾脏体积比预测肝硬化门静脉高压症的严重程度. 腹部外科, 2016, 29(3): 187-192. |
| 163. | 张宇, 文天夫, 陈哲宇, 等. 术前门静脉血流速度在门静脉高压症断流术后血栓形成中的预测价值. 中华外科杂志, 2009, 47(11): 825-828. |
| 164. | Lu MD, Yin XY, Xie XY, et al. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. Br J Surg, 2005, 92(11): 1393-1398. |
| 165. | Thomasset SC, Dennison AR, Garcea G. Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg, 2015, 39(5): 1150-1160. |
| 166. | Chen HW, Lai EC, Zhen ZJ, et al. Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. Int J Surg, 2011, 9(2): 188-191. |
| 167. | Chen R, Gan Y, Ge N, et al. Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within barcelona clinic liver cancer stage 0/a: a retrospective comparative study. J Vasc Interv Radiol, 2016, 27(12): 1829-1836. |
| 168. | Wang K, Liu G, Li J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol, 2015, 41(2): 236-242. |
| 169. | 段纪成, 刘凯, 吴孟超, 等. 经皮肝穿刺射频消融与再次肝切除对复发性小肝癌的随机对照研究. 肝胆外科杂志, 2015, 23(1): 15-17. |
| 170. | Chan AC, Poon RT, Cheung TT, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg, 2012, 36(1): 151-156. |
| 171. | Ho CM, Lee PH, Shau WY, et al. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery, 2012, 151(5): 700-709. |
| 172. | Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg, 2006, 243(3): 321-328. |
| 173. | Huang JW, Yan LN, Cheng ZY, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg, 2010, 252(6): 903-912. |
| 174. | 中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识. 实用肝脏病杂志, 2011, 14(4): 243-245. |
| 175. | Liang HH, Chen MS, Peng ZW, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. Ann Surg Oncol, 2008, 15(12): 3484-3493. |
| 176. | Chen MH, Yang W, Yan K, et al. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients—mathematic model, overlapping mode, and electrode placement process. Radiology, 2004, 232(1): 260-271. |
| 177. | Zhang L, Wang N, Shen Q, et al. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One, 2013, 8(10): e76119. |
| 178. | Abdelaziz A, Elbaz T, Shousha HI, et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an egyptian multidisciplinary clinic experience. Surg Endosc, 2014, 28(12): 3429-3434. |
| 179. | Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology, 2012, 262(1): 43-58. |
| 180. | Farina L, Weiss N, Nissenbaum Y, et al. Characterisation of tissue shrinkage during microwave thermal ablation. Int J Hyperthermia, 2014, 30(7): 419-428. |
| 181. | Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia, 2016, 32(3): 339-344. |
| 182. | Luo W, Zhang Y, He G, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis. World J Surg Oncol, 2017, 15(1): 126. |
| 183. | Ei S, Hibi T, Tanabe M, et al. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol, 2015, 22(4): 1294-1300. |
| 184. | Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology, 2015, 61(5): 1579-1590. |
| 185. | Chan AC, Cheung TT, Fan ST, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg, 2013, 257(4): 686-692. |
| 186. | Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res, 2011, 31(6): 2291-2295. |
| 187. | Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol, 2008, 43(6): 727-735. |
| 188. | Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology, 2005, 129(1): 122-130. |
| 189. | Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology, 2003, 228(1): 235-240. |
| 190. | Yong CC, Tsai MC, Lin CC, et al. Comparison of salvage living donor liver transplantation and local regional therapy for recurrent hepatocellular carcinoma. World J Surg, 2016, 40(10): 2472-2480. |
| 191. | Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl, 2013, 19(4): 411-419. |
| 192. | Yamashita Y, Yoshida Y, Kurihara T, et al. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: repeat hepatectomy versus salvage living donor liver transplantation. Liver Transpl, 2015, 21(7): 961-968. |
| 193. | Del Gaudio M, Ercolani G, Ravaioli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: university of bologna experience. Am J Transplant, 2008, 8(6): 1177-1185. |
| 194. | Lee HS, Choi GH, Joo DJ, et al. The clinical behavior of transplantable recurrent hepatocellular carcinoma after curative resection: implications for salvage liver transplantation. Ann Surg Oncol, 2014, 21(8): 2717-2724. |
| 195. | Majno PE, Sarasin FP, Mentha G, et al. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology, 2000, 31(4): 899-906. |
| 196. | Hu Z, Zhou J, Li Z, et al. Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus. Surgery, 2015, 157(2): 239-248. |
| 197. | Guerrini GP, Gerunda GE, Montalti R, et al. Results of salvage liver transplantation. Liver Int, 2014, 34(6): e96-e104. |
| 198. | Hu RH, Ho MC, Wu YM, et al. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin Transplant, 2005, 19(2): 175-180. |
| 199. | Kaido T, Mori A, Ogura Y, et al. Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection. Surgery, 2012, 151(1): 55-60. |
| 200. | Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl, 2004, 10(10): 1294-1300. |
| 201. | Ferrer-Fàbrega J, Forner A, Liccioni A, et al. Prospective validation of Ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology, 2016, 63(3): 839-849. |
| 202. | Yang PC, Ho CM, Hu RH, et al. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol, 2016, 8(31): 1309-1317. |
| 203. | Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002, 35(5): 1164-1171. |
| 204. | Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359(9319): 1734-1739. |
| 205. | Jin YJ, Chung YH, Kim JA, et al. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci, 2013, 58(6): 1758-1765. |
| 206. | Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol, 2019, 70(5): 893-903. |
| 207. | Koh PS, Chan AC, Cheung TT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford), 2016, 18(1): 72-78. |
| 208. | Cheng YC, Chen TW, Fan HL, et al. Transarterial chemo-embolization for intrahepatic multiple recurrent HCC after liver resection or transplantation. Ann Transplant, 2014, 19: 309-316. |
| 209. | Jin YJ, Lee JW, Lee OH, et al. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion. J Gastroenterol Hepatol, 2014, 29(5): 1056-1064. |
| 210. | Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res, 2009, 39(3): 231-240. |
| 211. | Dai WC, Cheung TT. Strategic overview on the best treatment option for intrahepaitc hepatocellular carcinoma recurrence. Expert Rev Anticancer Ther, 2016, 16(10): 1063-1072. |
| 212. | 曾昭冲. 消融治疗后复发肝癌及肝外转移的放射治疗. 中华医学杂志, 2015, 95(27): 2164-2166. |
| 213. | Bae SH, Park HC, Lim DH, et al. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys, 2012, 82(4): e603-607. |
| 214. | Su TS, Liang P, Lu HZ, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol, 2016, 113(2): 181-187. |
| 215. | Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol, 2014, 53(3): 399-404. |
| 216. | Seo YS, Kim MS, Yoo HJ, et al. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a markov model-based analysis. Cancer Med, 2016, 5(11): 3094-3101. |
| 217. | Nakazawa T, Adachi S, Kitano M, et al. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology, 2007, 73(1-2): 90-97. |
| 218. | Otsuka M, Ohara K, Takada Y, et al. Radiation therapy for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol, 2003, 8(3): 151-155. |
| 219. | Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys, 2012, 84(2): 355-361. |
| 220. | He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer, 2009, 115(12): 2710-2720. |
| 221. | Chang UK, Kim MS, Han CJ, et al. Clinical result of stereotactic radiosurgery for spinal metastasis from hepatocellular carcinoma: comparison with conventional radiation therapy. J Neurooncol, 2014, 119(1): 141-148. |
| 222. | Byun HK, Kim HJ, Im YR, et al. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiother Oncol, 2019, 133: 1-8. |
| 223. | 中华医学会放射肿瘤学分会, 中国生物医学工程学会精确放疗分会, 肝癌学组与消化系统肿瘤专家委员会, 等. 2016 年原发性肝癌放疗共识. 中华放射肿瘤学杂志, 2016, 25(11): 1141-1150. |
| 224. | Rivera L, Giap H, Miller W, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol, 2006, 12(35): 5729-5732. |
| 225. | 中华医学会核医学分会转移性骨肿瘤治疗工作委员会. 氯化锶[89Sr]治疗转移性骨肿瘤专家共识(2017 年版). 中华核医学与分子影像杂志, 2018, 38(6): 412-415. |
| 226. | Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology, 2016, 151(6): 1155-1163. |
| 227. | Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and rf ablation versus rf ablation alone: a prospective randomized trial. Radiology, 2012, 262(2): 689-700. |
| 228. | Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol, 2000, 32(5): 792-797. |
| 229. | Ali SA, Amin DH, Abdelkhalek YI. Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients. Jpn J Radiol, 2020, 38(5): 472-479. |
| 230. | Nakano M, Tanaka M, Kuromatsu R, et al. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Med, 2015, 4(12): 1836-1843. |
| 231. | Sohn W, Paik YH, Cho JY, et al. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol, 2015, 62(5): 1112-1121. |
| 232. | Zhang SM, Zeng ZC, Tang ZY, et al. Prognostic analysis of pulmonary metastases from hepatocellular carcinoma. Hepatol Int, 2008, 2(2): 237-243. |
| 233. | Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol, 2010, 17(10): 2795-2801. |
| 234. | Chen F, Sato K, Fujinaga T, et al. Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg, 2008, 32(10): 2213-2217. |
| 235. | Kobayashi S, Takahashi S, Kato Y, et al. Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, 2011, 18(4): 559-566. |
| 236. | Ha TY, Hwang S, Ahn CS, et al. Resection of metachronous adrenal metastasis after liver resection and transplantation for hepatocellular carcinoma. Dig Surg, 2014, 31(6): 428-435. |
| 237. | Kim SU, Kim DY, Park JY, et al. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol, 2008, 134(12): 1377-1384. |
| 238. | Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int, 2005, 25(2): 261-265. |
| 239. | Xu L, Wang J, Kim Y, et al. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology, 2015, 5(3): e1083671. |
| 240. | Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase Ⅲ trial. J Clin Oncol, 2020, 38(3): 193-202. |
| 241. | Sangro B, Park JW, Cruz D, et al. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. J Clin Oncol, 2016, 34(15 Suppl): TPS4147. |
| 242. | Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med, 2020, 382(20): 1894-1905. |
| 243. | Qin SK, Ren ZG, Meng ZQ, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol, 2020, 21(4): 571-580. |
| 244. | Chen Q, Shu C, Laurence AD, et al. Effect of huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018, 67(11): 2006-2016. |
- 1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
- 2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
- 3. 中华人民共和国卫计委. 原发性肝癌诊疗规范 (2017 年版). 中华消化外科杂志, 2017, 16(7): 635-647.
- 4. 中华人民共和国卫健委. 原发性肝癌诊疗规范(2019 年版). 中国实用外科杂志, 2020, 40(2): 121-138.
- 5. 四川大学华西医院肝癌 MDT 团队. 肝细胞癌切除术后复发转移的防治: 华西医院多学科专家共识. 中国普外基础与临床杂志, 2017, 24(8): 927-939.
- 6. Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371.
- 7. Ryder SD, British Society of gastroenterology. guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut, 2003, 52 Suppl 3(Suppl 3): i1-i8.
- 8. Force USPST. Grade definitions and suggestions for practice. 2012. https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions.
- 9. European Association For The Study Of The Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol, 2012, 56(4): 908-943.
- 10. Omata M, Cheng AL, Kokudo N, et al. Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int, 2017, 11(4): 317-370.
- 11. Park MJ, Kim YK, Lee MW, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology, 2012, 264(3): 761-770.
- 12. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced mr imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology, 2010, 256(3): 806-816.
- 13. Mitchell DG, Bruix J, Sherman M, et al. LI-RADS (liver imaging reporting and data system): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology, 2015, 61(3): 1056-1065.
- 14. Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol, 2016, 54(12): 1296-1305.
- 15. Johnson PJ. The BALAD-2 and GALAD biomarker models for hepatocellular carcinoma. Gastroenterol Hepatol (N Y), 2017, 13(4): 231-233.
- 16. Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol, 2016, 22(42): 9279-9287.
- 17. Huang C, Zhu XD, Ji Y, et al. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona clinic liver cancer (BCLC) stages 0 or B. BMC Cancer, 2017, 17(1): 58.
- 18. 中华医学会外科学分会肝脏外科学组. 肝细胞癌外科治疗方法的选择专家共识(2016 年第 3 次修订). 中华消化外科杂志, 2017, 16(2): 113-115.
- 19. Shen JY, Li C, Wen TF, et al. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the milan criteria after hepatectomy. J Surg Res, 2017, 209: 102-111.
- 20. Chen YK, Hsieh DS, Liao CS, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res, 2005, 25(6C): 4719-4725.
- 21. 文天夫. 转化切除是提高肝细胞癌切除率的重要途径. 中国普外基础与临床杂志, 2020, 27(2): 133-136.
- 22. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery, 1990, 107(5): 521-527.
- 23. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255(3): 405-414.
- 24. 周俭, 王征, 孙健, 等. 联合肝脏离断和门静脉结扎的二步肝切除术. 中华消化外科杂志, 2013, 12(7): 485-489.
- 25. 彭驰涵, 李川, 文天夫, 等. 原发性肝癌行 ALPPS 的适应证与禁忌证初探 (附 15 例报道). 中国普外基础与临床杂志, 2015, 22(10): 1183-1186.
- 26. Guiu B, Chevallier P, Denys A, et al. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol, 2016, 26(12): 4259-4267.
- 27. 刘畅, 张晓赟, 金谌, 等. 肝静脉系统栓堵术在第二阶段根治性肝癌切除术中的应用. 中国普外基础与临床杂志, 2019, 26(7): 841-846.
- 28. Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg, 1998, 15(6): 674-678.
- 29. Irtan S, Chopin-Laly X, Ronot M, et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int, 2011, 31(5): 740-743.
- 30. 余业勤, 汤钊猷, 周信达, 等. 大肝癌的分阶段治疗. 中华外科杂志, 1983, 21(2): 92-93.
- 31. Ronot M, Cauchy F, Gregoli B, et al. Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. HPB (Oxford), 2016, 18(8): 684-690.
- 32. Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res, 2018, 24(9): 2074-2081.
- 33. Kanai T, Hirohashi S, Upton MP, et al. Pathology of small hepatocellular carcinoma. Cancer, 1987, 60(4): 810-819.
- 34. Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg, 2009, 249(1): 118-123.
- 35. Hui AM, Takayama T, Sano K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol, 2000, 33(6): 975-979.
- 36. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl, 2005, 11(9): 1086-1092.
- 37. Shirabe K, Toshima T, Kimura K, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int, 2014, 34(6): 937-941.
- 38. Lee S, Kim SH, Lee JE, et al. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol, 2017, 67(3): 526-534.
- 39. Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg, 2016, 151(4): 356-363.
- 40. Li C, Shen JY, Zhang XY, et al. Predictors of futile liver resection for patients with barcelona clinic liver cancer stage B/C hepatocellular carcinoma. J Gastrointest Surg, 2018, 22(3): 496-502.
- 41. Li C, Liu JY, Peng W, et al. Liver resection versus transplantation for multiple hepatocellular carcinoma: a propensity score analysis. Oncotarget, 2017, 8(46): 81492-81500.
- 42. 中国医师协会肝癌专业委员会. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识 (2018 年版). 中国实用外科杂志, 2019, 39(1): 46-52.
- 43. Li J, Yan LN, Yang J, et al. Indicators of prognosis after liver transplantation in chinese hepatocellular carcinoma patients. World J Gastroenterol, 2009, 15(33): 4170-4176.
- 44. Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 2010, 59(7): 953-962.
- 45. Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology, 2013, 57(4): 1458-1468.
- 46. Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol, 2018, 33(2): 347-354.
- 47. Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol, 2015, 63(1): 83-92.
- 48. Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol, 2019, 37(24): 2141-2151.
- 49. Liu CL, Fan ST, Cheung ST, et al. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg, 2006, 244(2): 194-203.
- 50. Zheng JL, Shen S, Jiang L, et al. Outcomes of anterior approach major hepatectomy with diaphragmatic resection for single huge right lobe HCC with diaphragmatic invasion. Medicine (Baltimore), 2018, 97(36): e12194.
- 51. Man K, Fan ST, Ng IO, et al. Prospective evaluation of pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg, 1997, 226(6): 704-711.
- 52. Wen T, Chen Z, Yan L, et al. Continuous normothermic hemihepatic vascular inflow occlusion over 60 min for hepatectomy in patients with cirrhosis caused by hepatitis B virus. Hepatol Res, 2007, 37(5): 346-352.
- 53. Liu L, Wang ZW, Jiang SQ, et al. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One, 2013, 8(5): e64261.
- 54. Lee KF, Wong J, Cheung SYS, et al. Does intermittent pringle maneuver increase postoperative complications after hepatectomy for hepatocellular carcinoma? A randomized controlled trial. World J Surg, 2018, 42(10): 3302-3311.
- 55. Lu Q, Luo Y, Yuan CX, et al. Value of contrast-enhanced intraoperative ultrasound for cirrhotic patients with hepatocellular carcinoma: a report of 20 cases. World J Gastroenterol, 2008, 14(25): 4005-4010.
- 56. 方驰华, 张鹏, 罗火灵, 等. 增强现实导航技术联合吲哚菁绿分子荧光影像在三维腹腔镜肝切除术中的应用. 中华外科杂志, 2019, 57(8): 578-584.
- 57. Wu H, Lu Q, Luo Y, et al. Application of contrast-enhanced intraoperative ultrasonography in the decision-making about hepatocellular carcinoma operation. World J Gastroenterol, 2010, 16(4): 508-512.
- 58. Zhou C, Peng Y, Zhou K, et al. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. Hepatobiliary Surg Nutr, 2019, 8(1): 19-28.
- 59. Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol, 2016, 64(3): 594-600.
- 60. Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg, 2007, 245(1): 36-43.
- 61. Shen JY, Li C, Wen TF, et al. A simple prognostic score system predicts the prognosis of solitary large hepatocellular carcinoma following hepatectomy. Medicine (Baltimore), 2016, 95(31): e4296.
- 62. Eguchi S, Kanematsu T, Arii S, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery, 2008, 143(4): 469-475.
- 63. Han J, Li ZL, Xing H, et al. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford), 2019, 21(8): 962-971.
- 64. Makino Y, Yamanoi A, Kimoto T, et al. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol, 2000, 95(5): 1294-1300.
- 65. Buczkowski AK, Kim PT, Ho SG, et al. Multidisciplinary management of ruptured hepatocellular carcinoma. J Gastrointest Surg, 2006, 10(3): 379-386.
- 66. Kim BW, Kim YB, Wang HJ, et al. Risk Factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol, 2006, 12(1): 99-104.
- 67. Zhu WJ, Huang CY, Li C, et al. Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 2013, 14(12): 7101-7106.
- 68. Lee CW, Chan KM, Lee CF, et al. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg, 2011, 34(2): 53-62.
- 69. Nobuoka D, Kato Y, Gotohda N, et al. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep, 2010, 24(2): 521-528.
- 70. Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis b virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol, 2013, 31(29): 3647-3655.
- 71. 中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南. 北京: 人民卫生出版社, 2018: 35-38.
- 72. Ren ZG, Lin ZY, Xia JL, et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol, 2004, 10(19): 2791-2794.
- 73. Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg, 2009, 198(3): 313-318.
- 74. Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res, 2010, 40(10): 943-953.
- 75. Li KW, Wen TF, Li X, et al. The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion. Hepatogastroenterology, 2012, 59(118): 1944-1946.
- 76. Zhong JH, Li H, Li LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol, 2012, 38(4): 286-295.
- 77. Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond), 2018, 38(1): 61.
- 78. 程树群, 吴孟超, 陈汉, 等. 肝癌患者术后肝动脉化疗栓塞联合胸腺肽治疗预防复发的随机对照研究. 中华肿瘤杂志, 2004, 26(5): 305-307.
- 79. Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int, 2009, 3(3): 480-489.
- 80. He C, Peng W, Li C, et al. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. Medicine (Baltimore), 2017, 96(16): e6606.
- 81. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 2000, 356(9232): 802-807.
- 82. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology, 2000, 32(2): 228-232.
- 83. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol, 2006, 132(7): 458-465.
- 84. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg, 2007, 245(6): 831-842.
- 85. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg, 2009, 96(9): 975-981.
- 86. Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res, 2014, 44(5): 523-531.
- 87. Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends, 2014, 8(6): 333-338.
- 88. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2015, 16(13): 1344-1354.
- 89. Kudo M, Finn RS, Qin SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126): 1163-1173.
- 90. Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med, 2019, 8(1): 137-146.
- 91. Mizuta T, Ozaki I, Eguchi Y, et al. The Effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer, 2006, 106(4): 867-872.
- 92. Kakizaki S, Sohara N, Sato K, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol, 2007, 22(4): 518-522.
- 93. Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology, 2011, 54(2): 532-540.
- 94. Okita K, Izumi N, Matsui O, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol, 2015, 50(2): 191-202.
- 95. Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 2013, 31(28): 3501-3508.
- 96. Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol, 2010, 17(12): 3137-3144.
- 97. Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B E antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol, 2007, 47(5): 684-690.
- 98. Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg, 2015, 261(1): 56-66.
- 99. Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther, 2011, 33(10): 1104-1112.
- 100. Zhou XD, Tang ZY, Ma ZC, et al. Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. J Cancer Res Clin Oncol, 2009, 135(8): 1067-1072.
- 101. Si MS, Amersi F, Golish SR, et al. Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival. Am Surg, 2003, 69(10): 879-885.
- 102. Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol, 2005, 20(11): 1781-1787.
- 103. Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery, 2007, 141(2): 196-202.
- 104. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer, 2000, 89(3): 500-507.
- 105. Lee KF, Chong CCN, Fong AKW, et al. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center. Hepatobiliary Surg Nutr, 2018, 7(5): 320-330.
- 106. Sakamoto M, Hirohashi S, Tsuda H, et al. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol, 1989, 13(12): 1064-1067.
- 107. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg, 1989, 19(1): 98-129.
- 108. Takenaka K, Adachi E, Nishizaki T, et al. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology, 1994, 19(4): 889-894.
- 109. Ng IO, Guan XY, Poon RT, et al. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol, 2003, 199(3): 345-353.
- 110. Chen PJ, Chen DS, Lai MY, et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology, 1989, 96(2 Pt 1): 527-529.
- 111. Hodges KB, Cummings OW, Saxena R, et al. Clonal origin of multifocal hepatocellular carcinoma. Cancer, 2010, 116(17): 4078-4085.
- 112. Wang B, Xia CY, Lau WY, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg, 2013, 217(6): 1054-1062.
- 113. Morimoto O, Nagano H, Sakon M, et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol, 2003, 39(2): 215-221.
- 114. Esumi M, Aritaka T, Arii M, et al. Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res, 1986, 46(11): 5767-5771.
- 115. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet, 2003, 361(9361): 923-929.
- 116. Cheung ST, Chen X, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res, 2002, 62(16): 4711-4721.
- 117. Barry CT, D'Souza M, McCall M, et al. Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant, 2012, 12(2): 428-437.
- 118. Wilkens L, Bredt M, Flemming P, et al. Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J Pathol, 2000, 192(1): 43-51.
- 119. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 2012, 366(10): 883-892.
- 120. Miao R, Luo H, Zhou H, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol, 2014, 61(4): 840-849.
- 121. Xu XF, Xing H, Han J, et al. Risk Factors, Patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg, 2019, 154(3): 209-217.
- 122. Xing H, Zhang WG, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford), 2020, 22(5): 677-689.
- 123. Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg, 2017, 104(11): 1433-1442.
- 124. Meniconi RL, Komatsu S, Perdigao F, et al. Recurrent hepatocellular carcinoma: a western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery, 2015, 157(3): 454-462.
- 125. Zhang X, Li C, Wen T, et al. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J Gastroenterol Hepatol, 2015, 27(8): 933-940.
- 126. Wang DY, Liu L, Qi XS, et al. Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2015, 16(13): 5573-5578.
- 127. Mise Y, Hasegawa K, Shindoh J, et al. The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg, 2015, 262(2): 347-357.
- 128. Yamashita Y, Shirabe K, Tsuijita E, et al. Third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery, 2013, 154(5): 1038-1045.
- 129. Wu CC, Cheng SB, Yeh DC, et al. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg, 2009, 96(9): 1049-1057.
- 130. Poon RT, Fan ST, O'Suilleabhain CB, et al. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg, 2002, 195(3): 311-318.
- 131. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg, 2003, 238(5): 703-710.
- 132. Zou Q, Li J, Wu D, et al. Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg Oncol, 2016, 23(8): 2618-2626.
- 133. Yamashita S, Aoki T, Inoue Y, et al. Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Surgery, 2015, 157(3): 463-472.
- 134. Nakajima Y, Ko S, Kanamura T, et al. Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg, 2001, 192(3): 339-344.
- 135. 董家鸿, 郑树森, 陈孝平, 等. 肝切除术前肝脏储备功能评估的专家共识(2011 版). 中华消化外科杂志, 2011, 10(1): 20-25.
- 136. Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology, 1997, 26(5): 1176-1181.
- 137. Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg, 1999, 188(3): 304-309.
- 138. Shindoh J, D Tzeng CW, Vauthey JN. Portal vein embolization for hepatocellular carcinoma. Liver Cancer, 2012, 1(3-4): 159-167.
- 139. Siriwardana RC, Lo CM, Chan SC, et al. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study. World J Surg, 2012, 36(7): 1640-1646.
- 140. Tsujita E, Utsunomiya T, Ohta M, et al. Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older. Surgery, 2010, 147(5): 696-703.
- 141. Liu K, Chen Y, Wu X, et al. Laparoscopic liver re-resection is feasible for patients with posthepatectomy hepatocellular carcinoma recurrence: a propensity score matching study. Surg Endosc, 2017, 31(11): 4790-4798.
- 142. Chan AC, Poon RT, Chok KS, et al. Feasibility of laparoscopic re-resection for patients with recurrent hepatocellular carcinoma. World J Surg, 2014, 38(5): 1141-1146.
- 143. Hu M, Zhao G, Xu D, et al. Laparoscopic repeat resection of recurrent hepatocellular carcinoma. World J Surg, 2011, 35(3): 648-655.
- 144. Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer, 2016, 35: 25.
- 145. Kanazawa A, Tsukamoto T, Shimizu S, et al. Laparoscopic liver resection for treating recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, 2013, 20(5): 512-517.
- 146. Belli G, Cioffi L, Fantini C, et al. Laparoscopic redo surgery for recurrent hepatocellular carcinoma in cirrhotic patients: feasibility, safety, and results. Surg Endosc, 2009, 23(8): 1807-1811.
- 147. Halls MC, Cipriani F, Berardi G, et al. Conversion for unfavorable intraoperative events results in significantly worse outcomes during laparoscopic liver resection: lessons learned from a multicenter review of 2861 cases. Ann Surg, 2018, 268(6): 1051-1057.
- 148. Fan J, Wu ZQ, Zhou J, et al. Hepatocellular carcinoma associated with tumor thrombosis in the portal vein: the effects of different treatments. Hepatobiliary Pancreat Dis Int, 2003, 2(4): 513-519.
- 149. Ye JZ, Wang YY, Bai T, et al. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the asia-pacific region beyond the barcelona clinic liver cancer treatment algorithms: a review and update. Oncotarget, 2017, 8(54): 93258-93278.
- 150. Tantawi B, Cherqui D, Tran van Nhieu J, et al. Surgery for biliary obstruction by tumour thrombus in primary liver cancer. Br J Surg, 1996, 83(11): 1522-1525.
- 151. Qin LX, Ma ZC, Wu ZQ, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients. World J Gastroenterol, 2004, 10(10): 1397-1401.
- 152. Satoh S, Ikai I, Honda G, et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery, 2000, 128(5): 779-783.
- 153. Liu QY, Lai DM, Liu C, et al. A Special recurrent pattern in small hepatocellular carcinoma after treatment: bile duct tumor thrombus formation. World J Gastroenterol, 2011, 17(43): 4817-4824.
- 154. Hanaoka J, Shimada M, Ikegami T, et al. Hepatocellular carcinoma with massive bile duct tumor thrombus: report of a long-term survival. Hepatogastroenterology, 2008, 55(88): 2217-2220.
- 155. Moon DB, Hwang S, Wang HJ, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study. World J Surg, 2013, 37(2): 443-451.
- 156. Wong TC, Cheung TT, Chok KS, et al. Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus. HPB (Oxford), 2015, 17(5): 401-408.
- 157. Xu LB, Liu C. Hepatocellular carcinoma with bile duct tumor thrombus: extrahepatic bile duct preserving or not? Ann Surg, 2017, 266(6): e62-e63.
- 158. Chen XP, Wu ZD, Huang ZY, et al. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg, 2005, 92(3): 334-339.
- 159. Zhang X, Li C, Wen T, et al. Synchronous splenectomy and hepatectomy for patients with small hepatocellular carcinoma and pathological spleen: neutrophil to lymphocyte ratio changes can predict the prognosis. Oncotarget, 2017, 8(28): 46298-46311.
- 160. Zhang XY, Li C, Wen TF, et al. Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: a case-control study. World J Gastroenterol, 2015, 21(8): 2358-2366.
- 161. Zhang Y, Wen TF, Yan LN, et al. Preoperative predictors of portal vein thrombosis after splenectomy with periesophagogastric devascularization. World J Gastroenterol, 2012, 18(15): 1834-1839.
- 162. 张晓赟, 李川, 彭伟, 等. 血小板/脾脏体积比预测肝硬化门静脉高压症的严重程度. 腹部外科, 2016, 29(3): 187-192.
- 163. 张宇, 文天夫, 陈哲宇, 等. 术前门静脉血流速度在门静脉高压症断流术后血栓形成中的预测价值. 中华外科杂志, 2009, 47(11): 825-828.
- 164. Lu MD, Yin XY, Xie XY, et al. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. Br J Surg, 2005, 92(11): 1393-1398.
- 165. Thomasset SC, Dennison AR, Garcea G. Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg, 2015, 39(5): 1150-1160.
- 166. Chen HW, Lai EC, Zhen ZJ, et al. Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. Int J Surg, 2011, 9(2): 188-191.
- 167. Chen R, Gan Y, Ge N, et al. Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within barcelona clinic liver cancer stage 0/a: a retrospective comparative study. J Vasc Interv Radiol, 2016, 27(12): 1829-1836.
- 168. Wang K, Liu G, Li J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol, 2015, 41(2): 236-242.
- 169. 段纪成, 刘凯, 吴孟超, 等. 经皮肝穿刺射频消融与再次肝切除对复发性小肝癌的随机对照研究. 肝胆外科杂志, 2015, 23(1): 15-17.
- 170. Chan AC, Poon RT, Cheung TT, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg, 2012, 36(1): 151-156.
- 171. Ho CM, Lee PH, Shau WY, et al. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery, 2012, 151(5): 700-709.
- 172. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg, 2006, 243(3): 321-328.
- 173. Huang JW, Yan LN, Cheng ZY, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg, 2010, 252(6): 903-912.
- 174. 中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识. 实用肝脏病杂志, 2011, 14(4): 243-245.
- 175. Liang HH, Chen MS, Peng ZW, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. Ann Surg Oncol, 2008, 15(12): 3484-3493.
- 176. Chen MH, Yang W, Yan K, et al. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients—mathematic model, overlapping mode, and electrode placement process. Radiology, 2004, 232(1): 260-271.
- 177. Zhang L, Wang N, Shen Q, et al. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One, 2013, 8(10): e76119.
- 178. Abdelaziz A, Elbaz T, Shousha HI, et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an egyptian multidisciplinary clinic experience. Surg Endosc, 2014, 28(12): 3429-3434.
- 179. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology, 2012, 262(1): 43-58.
- 180. Farina L, Weiss N, Nissenbaum Y, et al. Characterisation of tissue shrinkage during microwave thermal ablation. Int J Hyperthermia, 2014, 30(7): 419-428.
- 181. Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia, 2016, 32(3): 339-344.
- 182. Luo W, Zhang Y, He G, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis. World J Surg Oncol, 2017, 15(1): 126.
- 183. Ei S, Hibi T, Tanabe M, et al. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol, 2015, 22(4): 1294-1300.
- 184. Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology, 2015, 61(5): 1579-1590.
- 185. Chan AC, Cheung TT, Fan ST, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg, 2013, 257(4): 686-692.
- 186. Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res, 2011, 31(6): 2291-2295.
- 187. Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol, 2008, 43(6): 727-735.
- 188. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology, 2005, 129(1): 122-130.
- 189. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology, 2003, 228(1): 235-240.
- 190. Yong CC, Tsai MC, Lin CC, et al. Comparison of salvage living donor liver transplantation and local regional therapy for recurrent hepatocellular carcinoma. World J Surg, 2016, 40(10): 2472-2480.
- 191. Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl, 2013, 19(4): 411-419.
- 192. Yamashita Y, Yoshida Y, Kurihara T, et al. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: repeat hepatectomy versus salvage living donor liver transplantation. Liver Transpl, 2015, 21(7): 961-968.
- 193. Del Gaudio M, Ercolani G, Ravaioli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: university of bologna experience. Am J Transplant, 2008, 8(6): 1177-1185.
- 194. Lee HS, Choi GH, Joo DJ, et al. The clinical behavior of transplantable recurrent hepatocellular carcinoma after curative resection: implications for salvage liver transplantation. Ann Surg Oncol, 2014, 21(8): 2717-2724.
- 195. Majno PE, Sarasin FP, Mentha G, et al. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology, 2000, 31(4): 899-906.
- 196. Hu Z, Zhou J, Li Z, et al. Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus. Surgery, 2015, 157(2): 239-248.
- 197. Guerrini GP, Gerunda GE, Montalti R, et al. Results of salvage liver transplantation. Liver Int, 2014, 34(6): e96-e104.
- 198. Hu RH, Ho MC, Wu YM, et al. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin Transplant, 2005, 19(2): 175-180.
- 199. Kaido T, Mori A, Ogura Y, et al. Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection. Surgery, 2012, 151(1): 55-60.
- 200. Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl, 2004, 10(10): 1294-1300.
- 201. Ferrer-Fàbrega J, Forner A, Liccioni A, et al. Prospective validation of Ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology, 2016, 63(3): 839-849.
- 202. Yang PC, Ho CM, Hu RH, et al. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol, 2016, 8(31): 1309-1317.
- 203. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002, 35(5): 1164-1171.
- 204. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359(9319): 1734-1739.
- 205. Jin YJ, Chung YH, Kim JA, et al. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci, 2013, 58(6): 1758-1765.
- 206. Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol, 2019, 70(5): 893-903.
- 207. Koh PS, Chan AC, Cheung TT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford), 2016, 18(1): 72-78.
- 208. Cheng YC, Chen TW, Fan HL, et al. Transarterial chemo-embolization for intrahepatic multiple recurrent HCC after liver resection or transplantation. Ann Transplant, 2014, 19: 309-316.
- 209. Jin YJ, Lee JW, Lee OH, et al. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion. J Gastroenterol Hepatol, 2014, 29(5): 1056-1064.
- 210. Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res, 2009, 39(3): 231-240.
- 211. Dai WC, Cheung TT. Strategic overview on the best treatment option for intrahepaitc hepatocellular carcinoma recurrence. Expert Rev Anticancer Ther, 2016, 16(10): 1063-1072.
- 212. 曾昭冲. 消融治疗后复发肝癌及肝外转移的放射治疗. 中华医学杂志, 2015, 95(27): 2164-2166.
- 213. Bae SH, Park HC, Lim DH, et al. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys, 2012, 82(4): e603-607.
- 214. Su TS, Liang P, Lu HZ, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol, 2016, 113(2): 181-187.
- 215. Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol, 2014, 53(3): 399-404.
- 216. Seo YS, Kim MS, Yoo HJ, et al. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a markov model-based analysis. Cancer Med, 2016, 5(11): 3094-3101.
- 217. Nakazawa T, Adachi S, Kitano M, et al. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology, 2007, 73(1-2): 90-97.
- 218. Otsuka M, Ohara K, Takada Y, et al. Radiation therapy for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol, 2003, 8(3): 151-155.
- 219. Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys, 2012, 84(2): 355-361.
- 220. He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer, 2009, 115(12): 2710-2720.
- 221. Chang UK, Kim MS, Han CJ, et al. Clinical result of stereotactic radiosurgery for spinal metastasis from hepatocellular carcinoma: comparison with conventional radiation therapy. J Neurooncol, 2014, 119(1): 141-148.
- 222. Byun HK, Kim HJ, Im YR, et al. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiother Oncol, 2019, 133: 1-8.
- 223. 中华医学会放射肿瘤学分会, 中国生物医学工程学会精确放疗分会, 肝癌学组与消化系统肿瘤专家委员会, 等. 2016 年原发性肝癌放疗共识. 中华放射肿瘤学杂志, 2016, 25(11): 1141-1150.
- 224. Rivera L, Giap H, Miller W, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol, 2006, 12(35): 5729-5732.
- 225. 中华医学会核医学分会转移性骨肿瘤治疗工作委员会. 氯化锶[89Sr]治疗转移性骨肿瘤专家共识(2017 年版). 中华核医学与分子影像杂志, 2018, 38(6): 412-415.
- 226. Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology, 2016, 151(6): 1155-1163.
- 227. Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and rf ablation versus rf ablation alone: a prospective randomized trial. Radiology, 2012, 262(2): 689-700.
- 228. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol, 2000, 32(5): 792-797.
- 229. Ali SA, Amin DH, Abdelkhalek YI. Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients. Jpn J Radiol, 2020, 38(5): 472-479.
- 230. Nakano M, Tanaka M, Kuromatsu R, et al. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Med, 2015, 4(12): 1836-1843.
- 231. Sohn W, Paik YH, Cho JY, et al. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol, 2015, 62(5): 1112-1121.
- 232. Zhang SM, Zeng ZC, Tang ZY, et al. Prognostic analysis of pulmonary metastases from hepatocellular carcinoma. Hepatol Int, 2008, 2(2): 237-243.
- 233. Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol, 2010, 17(10): 2795-2801.
- 234. Chen F, Sato K, Fujinaga T, et al. Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg, 2008, 32(10): 2213-2217.
- 235. Kobayashi S, Takahashi S, Kato Y, et al. Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, 2011, 18(4): 559-566.
- 236. Ha TY, Hwang S, Ahn CS, et al. Resection of metachronous adrenal metastasis after liver resection and transplantation for hepatocellular carcinoma. Dig Surg, 2014, 31(6): 428-435.
- 237. Kim SU, Kim DY, Park JY, et al. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol, 2008, 134(12): 1377-1384.
- 238. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int, 2005, 25(2): 261-265.
- 239. Xu L, Wang J, Kim Y, et al. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology, 2015, 5(3): e1083671.
- 240. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase Ⅲ trial. J Clin Oncol, 2020, 38(3): 193-202.
- 241. Sangro B, Park JW, Cruz D, et al. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. J Clin Oncol, 2016, 34(15 Suppl): TPS4147.
- 242. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med, 2020, 382(20): 1894-1905.
- 243. Qin SK, Ren ZG, Meng ZQ, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol, 2020, 21(4): 571-580.
- 244. Chen Q, Shu C, Laurence AD, et al. Effect of huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018, 67(11): 2006-2016.